



**Wrightington,  
Wigan and Leigh**  
NHS Foundation Trust

**Information Governance**

Wrightington Hospital  
Hall Lane  
Appley Bridge  
Lancashire  
WN6 9EP

Tel: 01257 256284  
Email: [FOI@wwl.nhs.uk](mailto:FOI@wwl.nhs.uk)  
Web: [www.wwl.nhs.uk](http://www.wwl.nhs.uk)

Ref: FOI2019/5649

Date Received: 11<sup>th</sup> September 2019

Response Due: 6<sup>th</sup> November 2019

5<sup>th</sup> November 2019

Dear

**INFORMATION REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000**

**You asked:**

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the following conditions.

Treatment	Total	Acute Trust Patients (Indication not recorded)	Outpatients via Homecare					
			Rheumatoid Arthritis	Ankylosing Spondylitis	Psoriatic Arthritis	Psoriasis	Crohns disease	Ulcerative Colitis
Abatacept (Orencia)	42		42					
Adalimumab biosimilar [Amgevita]	102		38	28	34		1	1
Adalimumab biosimilar [Hulio]	0							
Adalimumab [Humira]	409	2	75	65	56	41	134	36
Adalimumab biosimilar [Hyrimoz]	0							
Adalimumab biosimilar [Imraldi]	0							
Apremilast (Otezla)	8	4					4	
Baricitinib (Olumiant)	15		15					
Brodalumab (Kyntheum)	0							
Certolizumab (Cimzia)	27		15	5	6		1	
Dimethyl Fumarate (Skilarence)	21	21						
Etanercept (Enbrel)	50		23	11	14	2		
Etanercept Biosimilar (Benepali)	194		121	36	37			
Etanercept Biosimilar (Erelzi)	0							
Golimumab (Simponi)	30		5	6	18			1
Guselkumab (Tremfya)	0							
Infliximab [Flixabi]	0							
Infliximab [Inflectra]	90	61					19	10

Infliximab [Remicade]	<b>9</b>	9						
Infliximab [Remsima]	<b>0</b>							
Ixekizumab (Taltz)	<b>0</b>							
Rituximab (Mabthera)	<b>24</b>	24						
Rituximab Biosimilar (Rixathon)	<b>1</b>	1						
Rituximab Biosimilar (Truxima)	<b>136</b>	136						
Sarilumab (Kevzara)	<b>0</b>							
Secukinumab (Cosentyx)	<b>55</b>			12	18	25		
Tildrakizumab (Ilumetri)	<b>0</b>							
Tocilizumab (Ro Actemra)	<b>68</b>		68					
Tofacitinib (Xeljanz)	<b>5</b>						5	
Ustekinumab (Stelara)	<b>92</b>				4	34	54	
Vedolizumab (Entyvio)	<b>80</b>						75	5

I trust that this information is helpful to you, however if you are not entirely satisfied with this response please do not hesitate to contact the Information Governance Department on 01257 488271. If we do not hear from you within 28 days we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'M. Fleming', with a large, sweeping flourish extending to the right.

Mary Fleming  
Chief Operating Officer

**PLEASE NOTE:**

The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication, would require the permission of the copyright holder. You must ensure you gain their permission before reproducing any third party information.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Wrightington Hospital, Hall Lane, Appley Bridge, Wigan, WN6 9EP

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. Generally the ICO cannot make a decision unless you have exhausted the complaints procedure at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF